Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alnylam Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

84 comunicati stampa

Guarda tutti i comunicati
09/11/2026
Industria
Salute
Medicina - Varie
Sanità
Farmaceutica
Cardiologia
Biotecnologia
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/11/2026
Finanza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
Medicina - Varie
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/11/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/11/2026
Eventi
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Farmaceutica
Salute
Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
23/10/2026
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Web e Social Network
Eventi
Industria
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
15/10/2026
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/09/2026
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/09/2026
Eventi
Web e Social Network
Biotecnologia
Sanità
Salute
Farmaceutica
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/08/2026
Eventi
Industria
Cardiologia
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
Medicina - Varie
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
24/08/2026
Eventi
Analisi di mercato
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0